InspireMD chair to retire after 2027 meeting

InspireMD, Inc. reported that Board Chair Paul Stuka has decided not to seek reelection as a Class I director at the company’s 2027 Annual Meeting of Stockholders and plans to retire from the Board at that time.

Rhea-AI Filing Summary

InspireMD, Inc. reported that Board Chair Paul Stuka has decided not to seek reelection as a Class I director at the company’s 2027 Annual Meeting of Stockholders and plans to retire from the Board at that time.

The company states that his decision does not result from any disagreement regarding operations, policies, or practices. Stuka currently serves as Chair of the Board, Chair of the Compensation Committee, and as a member of the Audit and Nominating and Corporate Governance Committees, and he expects to continue in these roles until his term expires. The Nominating and Corporate Governance Committee plans to identify and evaluate suitable candidates as part of Board succession planning.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Notification date: May 20, 2026 Retirement timing: 2027 Annual Meeting Filing sign-off date: May 22, 2026

3 metrics

Notification date May 20, 2026 Date Paul Stuka informed InspireMD of his decision

Retirement timing 2027 Annual Meeting When Stuka’s term as Class I director ends

Filing sign-off date May 22, 2026 Date the report was signed by the CEO

Key Terms

Emerging growth company, Nominating and Corporate Governance Committee, Compensation Committee, Audit Committee

4 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nominating and Corporate Governance Committee financial

"a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

Compensation Committee financial

"the Chair of the Compensation Committee of the Board"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Audit Committee financial

"and a member of the Audit Committee and the Nominating and Corporate Governance Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Board change did InspireMD (NSPR) disclose in this 8-K?

InspireMD disclosed that Board Chair and Class I director Paul Stuka has decided not to seek reelection at the 2027 Annual Meeting and plans to retire from the Board when his current term expires, beginning a formal succession process for his roles.

When will InspireMD (NSPR) director Paul Stuka retire from the Board?

Paul Stuka plans to retire from InspireMD’s Board at the company’s 2027 Annual Meeting of Stockholders, when his current term as a Class I director ends. Until then, he expects to continue serving as Board Chair and committee member.

Did Paul Stuka cite any disagreement with InspireMD (NSPR) in his decision?

No. InspireMD states that Paul Stuka’s decision to retire and not seek reelection did not result from any disagreement with the company regarding its operations, policies, practices, or other matters, indicating a planned and orderly Board transition process.

What Board roles does Paul Stuka currently hold at InspireMD (NSPR)?

Paul Stuka is currently Chair of the Board, Chair of the Compensation Committee, and a member of the Audit Committee and the Nominating and Corporate Governance Committee. He expects to continue in these positions until his term ends at the 2027 Annual Meeting.

How is InspireMD (NSPR) handling Board succession after Paul Stuka’s planned retirement?

InspireMD’s Nominating and Corporate Governance Committee plans to identify and evaluate suitable candidates for the Board as part of succession planning, aiming to ensure an orderly transition when Paul Stuka’s Class I director term ends at the 2027 Annual Meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:05 PM EDT Learn about SEC filing dates

false 0001433607 0001433607 2026-05-20 2026-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2026

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35731		26-2123838
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6303 Waterford District Drive, Suite 215 Miami, Florida 33126		6744832
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 776-6804

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NSPR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the “Company”) of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the “Board”) at the Company’s 2027 Annual Meeting of Stockholders (the “2027 Annual Meeting”) and to retire from the Board. Mr. Stuka’s decision did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, practices or otherwise.

Mr. Stuka is currently the Chair of the Board, the Chair of the Compensation Committee of the Board, and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board. Mr. Stuka currently expects to continue to serve in such capacities until his term as a Class I director expires at the 2027 Annual Meeting. As part of succession planning, the Nominating and Corporate Governance Committee of the Board plans to identify and evaluate suitable candidates for the Board.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INSPIREMD, INC.
Date: May 22, 2026	By:	/s/ Marvin Slosman
	Name:	Marvin Slosman
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB